Kailera Therapeutics Statistics
Total Valuation
KLRA has a market cap or net worth of $2.70 billion. The enterprise value is $2.13 billion.
Important Dates
The last earnings date was Tuesday, May 26, 2026, after market close.
| Earnings Date | May 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KLRA has 129.57 million shares outstanding.
| Current Share Class | 129.57M |
| Shares Outstanding | 129.57M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 9.12% |
| Float | 58.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.82 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.67, with a Debt / Equity ratio of 0.02.
| Current Ratio | 9.67 |
| Quick Ratio | 9.53 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -39.05% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.45M |
| Employee Count | 145 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 48.06 |
| Average Volume (20 Days) | 1,038,156 |
Short Selling Information
The latest short interest is 2.60 million, so 2.01% of the outstanding shares have been sold short.
| Short Interest | 2.60M |
| Short Previous Month | 2.69M |
| Short % of Shares Out | 2.01% |
| Short % of Float | 4.45% |
| Short Ratio (days to cover) | 5.90 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -222.54M |
| Pretax Income | -209.84M |
| Net Income | -209.84M |
| EBITDA | -222.19M |
| EBIT | -222.54M |
| Earnings Per Share (EPS) | -$7,005.54 |
Full Income StatementBalance Sheet
The company has $519.17 million in cash and $10.47 million in debt, giving a net cash position of $571.45 million or $4.41 per share.
| Cash & Cash Equivalents | 519.17M |
| Total Debt | 10.47M |
| Net Cash | 571.45M |
| Net Cash Per Share | $4.41 |
| Equity (Book Value) | 560.28M |
| Book Value Per Share | -14,425.53 |
| Working Capital | 475.48M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$170.32 million and capital expenditures -$2.09 million, giving a free cash flow of -$172.41 million.
| Operating Cash Flow | -170.32M |
| Capital Expenditures | -2.09M |
| Depreciation & Amortization | 348,000 |
| Net Borrowing | 100.00M |
| Free Cash Flow | -172.41M |
| FCF Per Share | -$1.33 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |